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SECRETORY leukocyte protease inhibitor (SLPI) is a well-
known protease inhibitor. Its function is thought to
be protease/protease-inhibitor balance. Free proteo-
lytic  activity,  mainly  pancreatic  elastase,  anionic
trypsin  and granulocytic  elastase, has been demon-
strated in faecal extracts from patients with ulcerative
colitis.  We  wanted  to  verify  that  SLPI  is  actually
secreted from normal human colonic mucosa. Also,
we  wanted  to  ascertain  whether  studies  of  SLPI
secretion based on punch biopsies were dependent
on biopsy area or on biopsy circumference. Normal
colonic  mucosa  was  sampled  during  surgery  for
colonic  cancer.  A  total  of  36  samples  from  four
patients were used. Mucosa preparation was carried
out using a punch biopsy technique, and samples of 3,
4 and 6mm diameter were used. All media contained
SLPI  at  varying  concentrations. When  expressed  in
terms  of  the  sample  area,  the  secretion  per  milli-
metre-squared  seemed  to  decrease  with  increasing
area.  When  calculated  as  secretion  per  circumfer-
ence, secretion seemed to be constant. In conclusion,
SLPI  was  secreted  from  normal  human  colonic
mucosa. The SLPI secretion seemed dependent on the
circumference of the biopsy rather than on the area
of the biopsy.
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Introduction
Secretory  leukocyte  protease  inhibitor  (SLPI)  is  a
12kDa non-glycosylated  acid-stable antiprotease. Its
amino  acid  sequence  was  elucidated  in  1986.1 Its
inhibitory  activity  against  leukocytic  as  well  as
pancreatic elastase, cathepsin G, trypsin and chymo-
trypsin  is  well  known.1–4 It  was  first  found  in
cervical secretions5 and has since been found on a
variety of different cell surfaces. It appears in large
quantities in parotid secretions6 as well as in bron-
chial secretions.7,8 Its  role  is  thought  to be mainly
the  modulation  of  the  inflammatory  process.  In
addition, both  antibacterial and  antiviral  properties
have  been  reported.9–12 Increased  concentrations
have  been  reported  in  pneumonia  among  the
elderly.13
Large amounts of SLPI are swallowed3,14,15 and are
rapidly  degraded  in  gastric  and  duodenal  juices.16
Recently,  SLPI  was  demonstrated  in  the  intestinal
mucosa.17 Large amounts of free proteolytic activity,
mainly  pancreatic  elastase  and  trypsin,  have  been
found  in  secretions  from  patients  with  ulcerative
colitis.18,19 SLPI secretion and regulation in response
to  these  and  other  agents  is  thus  of  considerable
interest.  In  this  study,  we  wanted  to  verify  that
human  colonic  mucosa  was  capable  of  SLPI  secre-
tion. For future studies, we also wanted to ascertain
whether  studies  of  SLPI  based  on  punch  biopsies
were mainly dependent on biopsy area or on biopsy
circumference.
Materials and methods
Mucosal culture
The  procedure  was  approved  by  the  local  ethical
committee and  was performed in  accordance with
the Helsinki declaration. Tissue from macroscopically
normal colonic mucosa was taken during surgery for
the removal of colonic carcinoma from four patients
with no other known bowel disease. The mean age
of  the  patients  was  64  years.  The  mucosa  was
sampled  as  2–3cm  of  tissue  from  the  end  of  the
excised material, at the end opposite to the cancer.
It was placed in transport medium immediately after
the blood supply  was cut off,  and then washed in
separate  test  tubes  containing  transport  medium
three  times,  each  washing  lasting  2min. All  media
were  obtained  from  Gibco,  Life  Technologies  AB
(Sweden).
The  transport  medium  consisted  of  500ml  of
Minimum Essential Medium (MEM) with Earle’s Salts,
with  L-glutamine  (catalogue  number  31095–086),
ISSN 0962-9351 print/ISSN 1466-1861 online/01/050269-04 © 2001 Taylor & Francis Ltd 269
DOI: 10.1080/09629350120093740
Short Communication
Mediators of Inflammation, 10, 269–272 (2001)5ml  of  0.1 mM  MEM  non-essential  amino  acids
(catalogue  number  11140–35),  10ml  of  sodium
pyruvate  (catalogue  number  11360–039),  5ml  of
PEST (catalogue number 15140–114), and 0.5ml of
gentamycin sulphate (catalogue number 5750–037).
The  culture  medium  was  the  same  but  10%  foetal
calf serum was added. In the laboratory, the mucosa
was  carefully  dissected  with  scissors  and  samples
punched  out  with  a  KAI  sterile  disposable  biopsy
punch  (Stille,  Sweden).  Nine  punch  biopsies  were
taken from each of the patients. Biopsy diameters of
3,  4  and  6mm  were  used. Three  biopsies  of  each
size  were  taken. A  total  of  36  biopsies  were  thus
collected. After punching,  the biopsies were imme-
diately  placed  on  the  grid  of  a  10mm  diameter
Falcon cell culture insert, with 3.0 m m of HD (high
pore  density  membrane),  and  then  placed  in  the
12-well  companion plate for tissue culture  (Labora,
Sweden).  The  total  well  volume  was  3ml.  The
biopsies  were  incubated  for  24h  in  a  Modular
Incubator Chamber (Billrups, Rothenberg, CA, USA)
at 37.4°C. The Modular Incubator Chamber was pre-
ventilated for  10min  with  95%  O2 +  5% CO2. The
mucosa  samples  were  then  removed,  and  the
medium  was  collected  and  then  centrifuged  at
4000rpm  for 10min  at  +4°C. The supernatant was
carefully  collected  and  stored  in  aliquots  at  –70°C
until analysed for the presence of SLPI by a standard
enzyme-linked  immunosorbent  assay  (ELISA)  kit
obtained from RD Systems (Quantikine human SLPI
immunoassay). All analyses were performed in dupli-
cate  and  the  average  was  used  in  all  calculations.
Detailed information about specificity, accuracy and
precision is given in the ELISA manual. According to
this,  the  minimal  detectable  dose  is  typically  less
than  25ng/l.  At  mean  concentrations  of  109,  696
and 2026ng/l, the standard deviation is 8.7, 37.1 and
84.1,  respectively. The analysis of variance factorial
was used for statistical analysis.
Results
All  media contained SLPI at  varying  concentrations
ranging from 199 to 3258ng/l. Media concentrations
are presented in Table 1.
Secretion of SLPI expressed as nanograms per
litre per unit area (mm
2)
The  mean  calculated  secretion  per  unit  area  was
130.4ng/l  per  mm2 in  the  3mm  diameter samples
(range, 29.3–266.1ng/l), in the 4mm diameter sam-
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FIG. 1. SLPI calculated as mean concentration per area (light shading). In the 3mm diameter samples the mean concentration
was 130.4ng/l per mm
2 (SD = 83.4), in the 4mm samples it was 90ng/l per mm
2 (SD = 62.6), and in the 6mm diameter samples
it  was  61.3ng/l  per  mm
2 (SD  =  38.3).  When  calculated  as  mean  concentration  per  circumference  (dark  shading),  the
concentration in the 3mm diameter samples was 97.8ng/l permm (SD = 62.6), in the 4mm samples it was 90ng/l permm (SD
= 92.6), and in the 6mm diameter sample group it was 92ng/l permm (SD = 57.5). There was no significant difference in SLPI
concentration between sample groups when calculated as concentration per circumference. SLPI secretion decreased with
increasing sample area.
Table 1. Mean concentration of SLPI in growth medium (ng/l)
after 24h according to patient and the biopsy diameter
Patient 3mm
diameter
4mm
diameter
6mm
diameter
1 435.9 540.0 1073.8
2 429.1 324.9 541.7
3 1354.4 1575.6 2200.6
4 1466.3 2082.3 3113.3ples  the  mean  secretion  was  90.0ng/l  per  mm2
(range, 15.8–200.9ng/l),  and in  the 6mm  diameter
samples  it  was  61.3ng/l  per  mm2 (range,
12.3–115.3ng/l).  There  was  no  significant  differ-
ence  in  the  secretion per  mm2 between  the 3mm
diameter  samples  and  the  4mm  diameter  samples
(p >  0.13).  No  significant  difference  in  secretion
per  mm2 was  shown  between  the  4mm  diameter
samples and the 6mm diameter samples (p > 0.28).
There was, however,  a significant  difference in  the
secretion between the 3mm  diameter samples and
the  6mm  samples  (p =  0.0126),  The  secretion
seemed  to  decrease  with  increasing  area  (see
Fig. 1).
Secretion of SLPI expressed as nanograms per
litre per circumference of the sample (mm)
The calculated secretion per litre per circumference
in  the  3mm  diameter samples  was  97.8ng  (range,
22.0–199.6ng),  in  the  4mm  diameter  samples  the
secretion was 90.6ng (range, 24.7–200.9ng), and in
the  6mm  diameter  samples  it  was  92.0ng  (range,
24.9–172.9ng). There was  no significant  difference
in  secretion  calculated  as  secretion  per  circum-
ference  between  any  of  the  sample  groups  (p >
0.47) (see Fig. 1).
Discussion
SLPI is a protease secreted by a variety of mucosal
cells. Interest in the phenomenon has mainly been
directed  towards  the  upper  respiratory  tract.  Its
role is thought to be mainly downregulation of the
inflammatory  process. The  production  of  SLPI  has
also  been  demonstrated  in  the  large  and  small
intestines.17 In  this  study,  we  verified  that  SLPI  is
also  found  in  the  medium  from  cultured  normal
human  colonic  mucosa.  The  SLPI  concentration
after  24h  of  incubation  ranged  from  199  to
3258ng/l.  Interpersonal  differences  in  initial  SLPI
cell  content  might  be  an  explanation  for  variation
between patients with the same biopsy size. During
surgery, the tissue is subject to considerable trauma,
both  direct  cell  trauma  and  indirect  trauma,  e.g.
due  to  decreased  blood  supply.  Further  trauma  is
induced  during  punching  as  direct  cell  trauma.
Wounded  cells  might  also  interact  with  cells  in
their  close  vicinity. When  expressing  the  total  cell
production  of  SLPI  in  terms  of  the  sample  area,
there  was  a  significant  difference  in  secretion
between the 3mm samples and the 6mm samples.
The  secretion  per  mm2 seemed  to  decrease  with
increasing area. This might possibly be explained by
decreased metabolism in the centre of the biopsies
where cells are mainly in contact with the medium
from above and below. Cells located on the borders
of the biopsies are in contact with the medium also
on  almost  all  sides,  which  could  lead  to  a  some-
what higher metabolism. Another plausible explana-
tion  might  be  secretion  from  cells  caused  directly
or  indirectly  by  the  punching  procedure.  In  either
case, expressing  the secretion as a  function  of the
biopsy  circumference  would  be  a  possible  way  to
determine whether the cells located on the border
were  the  most  active  secreting  cells  in  the
biopsies.
No  significant  difference  was  observed  between
any of the samples when secretion was expressed as
secretion per circumference. In this study, the secre-
tion  therefore  seemed  to  be  influenced  mainly  by
the circumference of the biopsies (Fig. 1). This could
be  explained both by  decreased metabolism in  the
middle of the biopsy as well as direct physical injury
caused by the punching procedure. We hence con-
clude  that  SLPI  is  not  only  produced  in  normal
human colonic mucosa as indicated by earlier stud-
ies,  but  is  also  actually  secreted.  In  this  study,
secretion  seems  to  take  place  mainly  from  cells
located  on  the  edges  of  the  biopsies  rather  than
from all the cells cultured.
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